Related Experiment Video

Updated: Jul 12, 2026

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
08:06

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Published on: January 15, 2010

Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons

P Hantraye1, E Brouillet, R Ferrante

  • 1Unité de Recherche Associé Commissariat á l'Energie Atomique, Centre National de la Recherche Scientifique 2210, Service Hospitalier Frederic Joliot, Orsay, France.

Nature Medicine
|September 1, 1996
PubMed

Insights

7-Nitroindazole (7-NI) blocks neurotoxicity from 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in baboons, protecting against dopamine depletion and motor deficits. This suggests nitric oxide synthase inhibitors may treat Parkinson's disease.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure causes Parkinsonism-like symptoms.
  • Nitric oxide synthase (NOS) inhibition shows potential in blocking MPTP neurotoxicity.

Purpose of the Study:

  • To investigate the neuroprotective effects of 7-Nitroindazole (7-NI), a neuronal NOS inhibitor, against MPTP-induced toxicity in baboons.
  • To assess the role of nitric oxide in the pathogenesis of MPTP-induced Parkinsonism.

Main Methods:

  • MPTP was administered to baboons to induce Parkinsonian symptoms.
  • 7-Nitroindazole (7-NI) was administered to assess its protective effects.
  • Evaluated striatal dopamine levels, tyrosine hydroxylase-positive neurons in the substantia nigra, and motor and cognitive functions.

Main Results:

  • 7-NI significantly protected against MPTP-induced depletions of striatal dopamine.
  • 7-NI preserved tyrosine hydroxylase-positive neurons in the substantia nigra.
  • 7-NI ameliorated MPTP-induced motor and cognitive deficits.

Conclusions:

  • Nitric oxide plays a crucial role in MPTP-induced neurotoxicity.
  • Inhibitors of neuronal NOS, such as 7-NI, show promise as a therapeutic strategy for Parkinson's disease.

More Related Videos

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...